Article Text

Download PDFPDF
Addition of salmeterol to usual asthma pharmacotherapy may increase respiratory related deaths or life threatening experiences

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with asthma, is the addition of salmeterol to usual pharmacotherapy safe?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Allergy & immunology ★★★★★★☆ Respirology ★★★★★★☆


Embedded ImageDesign:

randomised placebo controlled trial (Salmeterol Multicenter Asthma Research Trial [SMART]).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (patients, healthcare providers, {data collectors}*, outcome assessors, and {data analysts}*).

Embedded ImageFollow up period:

28 weeks.

Embedded ImageSetting:

6163 sites in the US.

Embedded ImagePatients:

26 355 patients ⩾12 years of age (mean age 39 y, 63% women) who were diagnosed with asthma and currently receiving prescription asthma medication. Exclusion criteria included previous use of inhaled long acting β2 agonists and history of adverse reactions to sympathomimetic amine drugs.

Embedded ImageIntervention:

salmeterol, 42 μg, twice daily (on arising and before bed) …

View Full Text


Linked Articles

  • Glossary
    BMJ Publishing Group Ltd